Replies to post #82180 on Innovation Pharmaceuticals Inc (IPIX)

[cabel]

Wow Karin,... great job,.. that has to become a STICKY!!

[TheHound]

Thanks for spelling everything out Karin. Lots of new eyes here and it really helps. Easy to forget that.

As always, appreciate your time.

[faxedreceipts]

Has the numbness and tingling issue been addressed? I am doing DD on this and haven't come across anything, but that doesn't mean it hasn't been addressed.

Brilacidin is described as a peptide mimetic. It exerts antimicrobial effects by disrupting bacterial membranes. Brilacidin belongs to a new class of antibiotics the manufacturer has dubbed defensin-mimetics. Defensin-mimetics are designed to function similarly to existing host proteins called defensins. This novel mechanism translates to broad gram-positive and gram-negative activity. Current data on brilacidin show activity against ESBLs, and the manufacturer suggests activity against methicillin-resistant Staphylococcus aureus, Enterococcus faecium and NDM-1-producing K. pneumoniae. At this time, there is insufficient data regarding brilacidin’s coverage of Pseudomonas.

In addition, brilacidin has no activity against Acinetobacter baumannii. Recently, a phase 2 trial was completed that compared brilacidin with daptomycin for the treatment of acute bacterial skin and skin structure infections. Brilacidin met all objectives of efficacy and safety in this study. Of note, 65% to 87% of patients in the phase 2 trial experienced adverse events of numbness and tingling. The significance of this is unclear at this time, and the manufacturer is moving forward with a phase 2B study of brilacidin.

http://www.healio.com/infectious-disease/emerging-diseases/news/print/infectious-disease-news/%7B2d636304-7271-44d3-98a7-fd061a787883%7D/pipeline-or-pipe-dream-new-antibiotics-for-multidrug-resistant-gram-negative-bacilli

[$Pistol Pete$]

Great information and DD Karin

$CTIX

Pistol Pete!

[JUST 10-11-12]

nice chart!

[Steinvid]

Karin, you are sent from heaven..... Top nice work....;0)

Stay Green

[MinnieM]

This wedge looks interesting. It looks like it's ready to break out soon.

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart:

[MinnieM]

$CTIX Lead drug info, News, SEC filings, FDA trials, misc., and chart:

SEC filings: http://www.sec.gov/cgi-bin/browse-edgar?company=Cellceutix+Corp&match=&CIK=ctix&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Press Releases: http://cellceutix.com/category/press-release/

Recent News: http://finance.yahoo.com/q/h?s=CTIX+Headlines

Seeking Alpha focus articles on CTIX: http://seekingalpha.com/symbol/CTIX

Clinical trials: https://clinicaltrials.gov/ct2/results/displayOpt?flds=a&flds=b&flds=f&flds=c&flds=p&submit_fld_opt=on&=Update+Display&term=cellceutix&show_flds=Y

Management: http://cellceutix.com/team/

Product Pipeline: http://cellceutix.com/pipeline

When reading the iHub board posts:

B = Brilacidin, new class of antibiotic called defensin-mimetic
http://cellceutix.com/brilacidin/#sthash.YILNlO7Z.dpbs

K = Kevetrin, the oncology drug
http://cellceutix.com/kevetrin/#sthash.wHW2BJAD.dpbs

P = Prurisol, the psoriasis drug
http://cellceutix.com/prurisol/#sthash.GP0Dc7Qd.dpbs

FDA designations: 3 Orphans, 1 QIDP, 1 Fast-track and 1 Rare-Pediatric for CTIX
Orphan: Pancreatic, Ovarian, Retinoblastoma
QIDP: Brilacidin
Fast-track: Oral Mucositis (OM)
Rare-Pediatric: Retinoblastoma

Company Address:
100 Cumming Center, Suite 151-B
Beverly, MA 01915
978.236.8717 Phone
978.921.6564 Fax
E-mail: [e-mail]

CIK: 0001355250
All of above compiled by KarinCA

Three month Daily Chart:


Three year Weekly Chart: